[go: up one dir, main page]

WO2009083009A3 - Monoclonal antibodies against cd32b - Google Patents

Monoclonal antibodies against cd32b Download PDF

Info

Publication number
WO2009083009A3
WO2009083009A3 PCT/DK2008/050335 DK2008050335W WO2009083009A3 WO 2009083009 A3 WO2009083009 A3 WO 2009083009A3 DK 2008050335 W DK2008050335 W DK 2008050335W WO 2009083009 A3 WO2009083009 A3 WO 2009083009A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
antibodies against
against cd32b
antibodies
cd32b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2008/050335
Other languages
French (fr)
Other versions
WO2009083009A2 (en
Inventor
Edward Norbert Van Den Brink
Paul Parren
Jan Van De Winkel
Aran Frank Labrijn
Frank Everhardus Martinus Rebers
Esther Cornelia Wilhelmina Breij
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Priority to US12/811,637 priority Critical patent/US8802089B2/en
Priority to EP08867756.2A priority patent/EP2234641B1/en
Publication of WO2009083009A2 publication Critical patent/WO2009083009A2/en
Publication of WO2009083009A3 publication Critical patent/WO2009083009A3/en
Anticipated expiration legal-status Critical
Priority to US14/317,600 priority patent/US9663578B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
PCT/DK2008/050335 2008-01-03 2008-12-19 Monoclonal antibodies against cd32b Ceased WO2009083009A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/811,637 US8802089B2 (en) 2008-01-03 2008-12-19 Monoclonal antibodies against CD32B
EP08867756.2A EP2234641B1 (en) 2008-01-03 2008-12-19 Monoclonal antibodies against cd32b
US14/317,600 US9663578B2 (en) 2008-01-03 2014-06-27 Monoclonal antibodies against CD32b

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US987708P 2008-01-03 2008-01-03
DKPA200800006 2008-01-03
DKPA200800006 2008-01-03
US61/009,877 2008-01-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/811,637 A-371-Of-International US8802089B2 (en) 2008-01-03 2008-12-19 Monoclonal antibodies against CD32B
US14/317,600 Division US9663578B2 (en) 2008-01-03 2014-06-27 Monoclonal antibodies against CD32b

Publications (2)

Publication Number Publication Date
WO2009083009A2 WO2009083009A2 (en) 2009-07-09
WO2009083009A3 true WO2009083009A3 (en) 2009-08-27

Family

ID=40578114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050335 Ceased WO2009083009A2 (en) 2008-01-03 2008-12-19 Monoclonal antibodies against cd32b

Country Status (3)

Country Link
US (2) US8802089B2 (en)
EP (1) EP2234641B1 (en)
WO (1) WO2009083009A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9243069B2 (en) 2008-04-02 2016-01-26 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using the same
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL217296B1 (en) 2002-11-15 2014-07-31 Genmab As Human monoclonal antibodies against cd25
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
ES2897506T3 (en) 2003-01-09 2022-03-01 Macrogenics Inc Identification and modification of antibodies with variant Fc regions and methods of using them
AU2005244058B2 (en) 2004-05-10 2011-07-28 Macrogenics, Inc. Humanized FcgammaRIIB specific antibodies and methods of use thereof
US8785599B2 (en) 2006-06-26 2014-07-22 Macrogenics, Inc. FcγRIIB—specific antibodies and methods of use thereof
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
HRP20130163T1 (en) 2006-09-07 2013-03-31 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
KR20110111303A (en) * 2009-01-16 2011-10-10 글락소스미스클라인 엘엘씨 Treatment of Cancer with a Combination of Bendamustine and Anti-CD20 Antibodies
TWI409079B (en) * 2009-08-14 2013-09-21 Roche Glycart Ag Combination therapy of atypical fucosylated CD20 antibody and bendamustine
PT3904391T (en) * 2010-03-10 2024-10-14 Genmab As Monoclonal antibodies against c-met
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (en) * 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
MA41375A (en) 2015-01-22 2017-11-28 Lilly Co Eli BISPECIFIC IGG ANTIBODIES AND THEIR PREPARATION PROCESSES
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
CN107530376A (en) 2015-02-18 2018-01-02 恩立夫克治疗有限责任公司 Combined immunization therapy and cell factor control therapy for treatment of cancer
EP3285877B1 (en) 2015-04-21 2022-10-19 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
KR20180110141A (en) 2016-02-18 2018-10-08 엔리벡스 테라퓨틱스 리미티드 Combination of immunotherapy and cytokine regulating therapy to treat cancer
AU2017249435B2 (en) 2016-04-15 2024-05-02 Macrogenics, Inc. Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
EP3606952A1 (en) 2017-04-07 2020-02-12 Miltenyi Biotec GmbH POLYPEPTIDES WITH MUTANT HUMAN IgG4
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
UY38251A (en) 2018-06-01 2019-12-31 Novartis Ag BINDING MOLECULES AGAINST BCMA AND USES OF THEM
CU20210096A7 (en) 2019-05-21 2022-06-06 Novartis Ag CD19 BINDING MOLECULES
KR20230104651A (en) 2020-11-06 2023-07-10 노파르티스 아게 CD19 Binding Molecules and Uses Thereof
US20230272072A1 (en) * 2021-10-21 2023-08-31 Seismic Therapeutic, Inc. Dual targeted immune regulating compositions
CN120769862A (en) 2022-10-25 2025-10-10 赛斯米克治疗公司 Variant IgG FC polypeptides and their uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051999A2 (en) * 2003-11-26 2005-06-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Substance binding human igg fc receptor iib
WO2006028956A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
WO2006039418A2 (en) * 2004-09-30 2006-04-13 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor ii (cd32)
WO2006066078A2 (en) * 2004-12-15 2006-06-22 Magrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101333449B1 (en) 2003-12-10 2013-11-26 메다렉스, 엘.엘.시. Ip-10 antibodies and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051999A2 (en) * 2003-11-26 2005-06-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Substance binding human igg fc receptor iib
WO2006028956A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
WO2006039418A2 (en) * 2004-09-30 2006-04-13 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor ii (cd32)
WO2006066078A2 (en) * 2004-12-15 2006-06-22 Magrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RANKIN CHRISTOPHER T ET AL: "CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma", BLOOD 1 OCT 2006,, vol. 108, no. 7, 1 October 2006 (2006-10-01), pages 2384 - 2391, XP002522503 *
VERI MARIA-CONCETTA ET AL: "Monoclonal antibodies capable of discriminating the human inhibitory Fc gamma-receptor IIB (CD32B) from the activating Fc gamma-receptor IIA (CD32A): biochemical, biological and functional characterization", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 121, no. 3, 1 July 2007 (2007-07-01), pages 392 - 404, XP002498115, ISSN: 0019-2805 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US9243069B2 (en) 2008-04-02 2016-01-26 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using the same
US9469692B2 (en) 2008-04-02 2016-10-18 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Also Published As

Publication number Publication date
EP2234641A2 (en) 2010-10-06
US9663578B2 (en) 2017-05-30
US8802089B2 (en) 2014-08-12
US20110038869A1 (en) 2011-02-17
US20150004177A1 (en) 2015-01-01
WO2009083009A2 (en) 2009-07-09
EP2234641B1 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2010066803A3 (en) Human antibodies against human tissue factor
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2011130434A3 (en) Antibodies that bind human cd27 and uses thereof
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
WO2011110642A3 (en) Monoclonal antibodies against c-met
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
EP3539988A3 (en) Monoclonal antibodies against her2
MX350200B (en) Human antibodies and antibody-drug conjugates against cd74.
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2013063114A8 (en) Immunobinders directed against tnf
WO2011160119A3 (en) Anti-gd2 antibodies
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
MX345092B (en) Human anti-tau antibodies.
PH12012501991A1 (en) Tnf-alpha binding proteins
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
EA030777B9 (en) Anti-alpha synuclein binding molecules
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
WO2011112566A3 (en) Basigin binding proteins
MX360580B (en) Human anti-alpha-synuclein autoantibodies.
SG10201909377XA (en) Antibodies that bind human cd27 and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08867756

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008867756

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12811637

Country of ref document: US